What is Relmada Therapeutics' stock price target for 2024?

0 brokerages have issued 12-month target prices for Relmada Therapeutics' shares. Their RLMD share price targets range from $25.00 to $25.00. On average, they anticipate the company's stock price to reach $25.00 in the next year. This suggests a possible upside of 461.8% from the stock's current price. View analysts price targets for RLMD or view top-rated stocks among Wall Street analysts .

How have RLMD shares performed in 2024?

Relmada Therapeutics' stock was trading at $4.14 at the beginning of 2024. Since then, RLMD stock has increased by 7.5% and is now trading at $4.45. View the best growth stocks for 2024 here .

When is Relmada Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our RLMD earnings forecast .

How were Relmada Therapeutics' earnings last quarter?

Relmada Therapeutics, Inc. (NASDAQ:RLMD) posted its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.04.

What ETF holds Relmada Therapeutics' stock?

AdvisorShares Psychedelics ETF holds 72,123 shares of RLMD stock, representing 4.53% of its portfolio.

How do I buy shares of Relmada Therapeutics?

Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:RLMD

Relmada Therapeutics (RLMD) Stock Price, News & Analysis

→ The #1 Investment of the Decade… (From Porter & Company) (Ad)

Free RLMD Stock Alerts

$4.45

-0.20 (-4.30%)

(As of 04/15/2024 ET)

Compare

Today's Range: $4.41
▼
$4.73
50-Day Range: $4.44
▼
$6.80
52-Week Range: $2.36
▼
$7.22

Volume: 125,022 shs
Average Volume: 264,320 shs
Market Capitalization: $134.26 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $25.00

Get Relmada Therapeutics alerts:

Relmada Therapeutics MarketRank™ Stock Analysis

Analyst Rating: 0.00 Rating Score
Upside/Downside: 461.8% Upside
$25.00 Price Target
Short Interest: Bearish
5.60% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.45
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Acquiring Shares
$350,305 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($3.53) to ($2.86) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.37 out of 5 stars

Medical Sector

295th out of 929 stocks

Pharmaceutical Preparations Industry

129th out of 424 stocks

2.0

Analyst's Opinion

Amount of Analyst Coverage
Relmada Therapeutics has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.60% of the outstanding shares of Relmada Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Relmada Therapeutics has a short interest ratio ("days to cover") of 7.4.
Change versus previous month
Short interest in Relmada Therapeutics has recently decreased by 3.43%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Relmada Therapeutics does not currently pay a dividend.
Dividend Growth
Relmada Therapeutics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Relmada Therapeutics has received a 66.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Clinical research services for mood disorders" product. See details.
Environmental Sustainability
The Environmental Impact score for Relmada Therapeutics is -1.45.

2.7

News and Social Media Coverage

News Sentiment
Relmada Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Relmada Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
Only 2 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Relmada Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $350,305.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
13.50% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Relmada Therapeutics are expected to grow in the coming year, from ($3.53) to ($2.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Relmada Therapeutics is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Relmada Therapeutics is -1.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Relmada Therapeutics has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Relmada Therapeutics Stock (NASDAQ:RLMD)

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

RLMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RLMD Stock News Headlines

March 21, 2024 | seekingalpha.com

Relmada Therapeutics: Run Up Into Results May Resume Following This Drop

March 21, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Relmada Therapeutics Amidst Strong Phase 3 Trial Prospects and Financial Stability

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

March 20, 2024 | finance.yahoo.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2023 Earnings Call Transcript

March 20, 2024 | finanznachrichten.de

Relmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

March 20, 2024 | finance.yahoo.com

Q4 2023 Relmada Therapeutics Inc Earnings Call

March 19, 2024 | investorplace.com

RLMD Stock Earnings: Relmada Therapeutics Misses EPS for Q4 2023

March 19, 2024 | benzinga.com

Recap: Relmada Therapeutics Q4 Earnings

April 16, 2024 | InvestorPlace (Ad)

REVEALED: Elon Musk’s Secret A.I. Facility?

I recently shot this video outside what could be Elon Musk’s biggest secret. What’s happening inside these walls is so important that our government has declared it a matter of national security.

March 19, 2024 | finance.yahoo.com

Relmada Therapeutics Inc Reports Full-Year and Q4 2023 Financial Results

March 19, 2024 | prnewswire.com

Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

March 19, 2024 | msn.com

Options Volatility and Implied Earnings Moves Today, March 19, 2024

March 18, 2024 | msn.com

Relmada Therapeutics FY 2023 Earnings Preview

March 16, 2024 | finance.yahoo.com

RLMD Apr 2024 2.500 put

March 5, 2024 | prnewswire.com

Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

February 13, 2024 | investing.com

Relmada Therapeutics Inc (RLMD)

February 5, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Immunocore Holdings (IMCR), Thermo Fisher (TMO)

February 4, 2024 | thestreet.com

Relmada Therapeutics Inc.

February 2, 2024 | msn.com

Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying

February 1, 2024 | marketwatch.com

Relmada Therapeutics Shares Hit 52-Week High After Execs Buy Shares

February 1, 2024 | finance.yahoo.com

Relmada Therapeutics Inc CEO Sergio Traversa Acquires 100,000 Shares

January 30, 2024 | benzinga.com

Relmada Therapeutics Stock (NASDAQ:RLMD) Dividends: History, Yield and Dates

January 23, 2024 | morningstar.com

Relmada Therapeutics Inc RLMD

January 23, 2024 | finance.yahoo.com

Relmada Therapeutics, Inc.'s (NASDAQ:RLMD) market cap touched US$109m last week, benefiting both individual investors who own 39% as well as institutions

January 4, 2024 | realmoney.thestreet.com

Mizuho sees weakness in Relmada Therapeutics shares as buying opportunity

January 4, 2024 | marketwatch.com

Relmada Therapeutics Shares Slide as Medical Chief Exits

January 4, 2024 | finanznachrichten.de

Relmada Therapeutics, Inc.: Relmada Therapeutics Provides Corporate Update

See More Headlines

Receive RLMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RLMD
CUSIP: N/A
CIK: 1553643
Web: www.relmada.com
Phone: (786) 629-1376
Fax: N/A
Employees: 14
Year Founded: 2004

Price Target and Rating

Average Stock Price Target: $25.00
High Stock Price Target: $25.00
Low Stock Price Target: $25.00
Potential Upside/Downside: +463.1%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.28)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-98,790,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -93.44%
Return on Assets: -85.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.00
Quick Ratio: 8.00

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.84 per share
Price / Book: 1.56

Miscellaneous

Outstanding Shares: 30,170,000
Free Float: 26,101,000
Market Cap: $133.95 million
Optionable: Optionable
Beta: 0.19

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Sergio Traversa M.B.A. (Age 64)
Pharm.D., CEO & Director
Comp: $719.04k
Mr. Maged S. Shenouda M.B.A. (Age 60)
R.Ph., Chief Financial Officer
Comp: $450.35k
Mr. Charles S. Ence CPA (Age 59)
M.B.A., Chief Accounting & Compliance Officer
Comp: $568.68k
Dr. Paolo Manfredi M.D. (Age 62)
Ph.D., Chief Scientific Officer
Ms. Gina DiGuglielmo
VP & Head of Clinical Operations
Dr. Marco Pappagallo M.D. (Age 65)
Chief Clinical Officer
Mr. John Hixon
Head of Commercial
Dr. Richard M. Mangano (Age 74)
Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RLMD Stock Analysis - Frequently Asked Questions

What is Relmada Therapeutics' stock price target for 2024?: 0 brokerages have issued 12-month target prices for Relmada Therapeutics' shares. Their RLMD share price targets range from $25.00 to $25.00. On average, they anticipate the company's stock price to reach $25.00 in the next year. This suggests a possible upside of 461.8% from the stock's current price.
View analysts price targets for RLMD or view top-rated stocks among Wall Street analysts.
How have RLMD shares performed in 2024?: Relmada Therapeutics' stock was trading at $4.14 at the beginning of 2024. Since then, RLMD stock has increased by 7.5% and is now trading at $4.45.
View the best growth stocks for 2024 here.
When is Relmada Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our RLMD earnings forecast.
How were Relmada Therapeutics' earnings last quarter?: Relmada Therapeutics, Inc. (NASDAQ:RLMD) posted its quarterly earnings results on Tuesday, March, 19th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.04.

What ETF holds Relmada Therapeutics' stock?: AdvisorShares Psychedelics ETF holds 72,123 shares of RLMD stock, representing 4.53% of its portfolio.
How do I buy shares of Relmada Therapeutics?: Shares of RLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RLMD) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial